Thrombus Aspiration Catheter Market Size $2B to $4.6B (2026–2036) Q2 2026 Updated | Meridian Consensus

Decision-grade Market IntelligenceAny market · any geography

Layers Companies Methodology Pricing About Contact

Healthcare

currentUpdated yesterdayNext refresh May 29Live · since 40d ago

Boardroom-ready · 8 languages

Thrombus Aspiration Catheter Market

Name: Thrombus Aspiration Catheter Market
Creator: Meridian Consensus
Published: 2026-04-13T09:20:53.657Z
License: https://www.meridianconsensus.com/editorial-policy

Valued at $2.0B in 2025, growing at 8.1% to $4.6B by 2036. Moderately concentrated; the top three incumbents hold , led by .

Request the preview PDF

A 57-page institutional preview of the Thrombus Aspiration Catheter Market.

What's inside

Executive brief
Market sizing · 2020 – Q1 2026 history + 2026–2036 forecast
Meridian reconciliation vs peer estimates
Segmentation · product, application, channel, end-user
10-region analysis with country-level breakdowns
Competitive landscape + ranked share + Porter Five Forces
Value-chain economics
PESTLE and bull/base/bear scenarios
Patent landscape and regulatory watch
Sample investment-thesis chapter
Committee sign-off memo
Full source index

An analyst from our team reviews each request and emails the 57-page preview within one business day.

Takeaways

North America · 42% revenue share ($823M)·Penumbra Inc. · 35% share ($684M)·Direct OEM Sales (neuro & cardiac specialty reps) · 44% of market·Growth of $2.7B · 2025–2036

What are you trying to answer?

Smart-routing TOC · 3 intents

U.1

Strategy / corp dev / market entry

Sizing the opportunity

How big is the Thrombus Aspiration Catheter today, where is it growing fastest, and what is its three-path-triangulated forecast?

Size rigor + forecast →

U.2

Investment / M&A / equity research

Reading the competitive landscape

Who leads the Thrombus Aspiration Catheter, by how much, and which incumbents are losing share to which challengers?

Competitive landscape →

Full analysis · 30 chapters

Inside the commissioned report.

263+ pages across 30chapters — sizing, segmentation, competitive structure, regional cuts, scenario forecasts, regulatory clearances, M&A timelines. Every angle a senior buyer asks about, in one place.

01 / 306 pp

Executive Brief

Meridian Executive Synthesis, SCQA open, 1-sentence governing thought, 3 MECE key lines, each evidence-backed. The single page institutional buyers read first.

02 / 3014 pp

Executive Briefing

Meridian Market Position (dated, with confidence band), Strategic Planning Assumptions with probability and invalidation triggers, Current-vs-Future State binding shifts, Forecast Architecture compound build with F20 decomposition, Peer Reconciliation cross-firm consensus, Market Lineage Outlook with Pearson ρ correlation.

Same rigor · your market

This published preview · your commissioned report.

8 dimensions · side-by-side

Dimension

This published preview

Your commissioned report

01Market size & forecast

Headline 2025 figure ($2.0B) and 2036 forecast ($4.6B), year-by-year build to 2036.

Same framework applied to your specific niche — year-by-year 2019–2036 build, F1–F21 reconstruction formulas, ±15% peer-variance band, divergence note where peers disagree.

02Competitive landscape

Analyst take · Healthcare desk

The thesis.

By Meridian Consensus Editorial Committee, Editorial Committee

May 22, 2026 · Committee-reviewed

Our desk sees the thrombus aspiration catheter market compounding at 8.1% through 2036 on STEMI volume and device iteration, though Penumbra's 35% fortress creates switching costs that newer entrants can't breach without clinical breakthroughs or reimbursement cracks.

The thrombus aspiration catheter market sat at $1.96B at year-end 2025. We're tracking a 8.1% CAGR through 2036 as aging demographics collide with expanding interventional cardiology infrastructure in emerging markets. North America held 42% of global revenue, anchored by dense cath lab networks and favorable Medicare reimbursement. Asia-Pacific is the fastest-growing theater—our reckoning puts it at double-digit expansion as India, China, and Southeast Asian nations modernize acute coronary syndrome protocols. The technology has evolved past simple manual aspiration: hydrogel-coated lumens, integrated pressure sensors, rapid-exchange platforms that cut procedural time and distal embolization risk. Aspiration catheters are now essential adjuncts in primary PCI workflows despite mixed clinical trial outcomes in the 2010s.

Four catalysts underpin the 9.0% trajectory. First, STEMI presentations continue rising as mechanical thrombectomy cases expand. Second, regulatory tailwinds: FDA and CE Mark approvals are accelerating for next-generation devices with atraumatic tip designs and enhanced radiopacity. Third, mounting clinical evidence from registries shows improved door-to-balloon times and reduced no-reflow phenomena when aspiration precedes stent deployment in high thrombus-burden lesions. Fourth, hospital procedural volume recovered post-pandemic, and value-based care models now reward first-pass success rates—hospitals are incentivized to use aspiration technology to minimize repeat interventions and length-of-stay metrics. The shift toward radial access and smaller French-size compatibility expands addressable procedures beyond traditional femoral cases.

Market structure

Size rigor.

Addressable market, unit economics, value chain, and trade flows. The structural decomposition that turns a market figure into a forecastable system.

Unit economics triangulation

24.6% variance

Avg unit price · supply-side

$1,850

per thrombus aspiration catheter procedure (device + disposables)

Range: $1,200–$2,800

src: CMS 2024 Medicare reimbursement for CPT 92973 percutaneous transluminal coronary thrombectomy mechanical ($1,200-$1,800 facility fee) plus device cost ($600-$1,200 per catheter) derived from Boston Scientific and Penumbra ASP disclosures in 2023-2024 10-K filings, blended average $1,850 per procedure

Primary evidence

Market evidence.

Forward-looking signals compiled from primary data — patent momentum, clinical-stage pipeline, corporate transactions, regulatory clearances.

Patent landscape

Registry-verified

Active patents

100

Across 10 top assignees

Filing velocity · 5yr

+104%

vs prior 5-year window

Filings trend · 10yr

Strategic framing

Buyer · tech · competition · scenarios.

Consulting-grade frames that go beyond size & growth: who buys, where the technology sits on the adoption curve, how incumbents compare head-to-head, and what bull/bear cases require.

Buyer persona · decision unit

Primary buyer

Director of Interventional Cardiology / Cath Lab Director

Cardiovascular Services / Interventional Radiology

Budget

$500K–$3M per year

Cycle

6–12 months

Influencers

Market dynamics

Driver

Rising global STEMI incidence

Aging populations and metabolic syndrome prevalence in North America and Europe drive 3.2% annual growth in acute myocardial infarction cases requiring emergent mechanical thrombectomy with aspiration catheters.

Driver

Neurovascular thrombectomy adoption

Expansion of comprehensive stroke center networks and extended treatment windows (up to 24 hours) increase mechanical thrombectomy volumes, with large-bore aspiration catheters capturing 60% of neuro-intervention procedures.

Driver

Regulatory approvals for peripheral indications

FDA clearances for deep vein thrombosis and pulmonary embolism aspiration systems open new clinical segments, with Penumbra Indigo and Boston Inari systems demonstrating clot removal efficacy.

Industry structure

Porter forces · SWOT.

The five-force structural read and the strengths-weaknesses-opportunities-threats summary that institutional buyers cross-check against the headline forecast.

Porter five forces

Confirmed

Recent industry events

Q1 2025

Search ↗

Medtronic plc reported expanded use of its Export Advance aspiration catheter in emerging markets following regulatory approvals in Southeast Asia and Latin America.

Q2 2024

Search ↗

Boston Scientific launched next-generation Fetch 2 aspiration catheter with enhanced torque control and rapid exchange platform at major interventional cardiology conferences.

Adjacency

Related markets.

All markets

Competitive overlap

Markets sharing these incumbents.

3 adjacent

Interventional Cardiology Market

$18.5B

Healthcare6.3%

4 shared incumbents

Boston Scientific · Medtronic plc · Terumo Corporation · Teleflex

Thrombectomy Devices Market

$1.9B

Healthcare6.5%

4 shared incumbents

Penumbra Inc. · Medtronic plc · Johnson & Johnson (Cerenovus) · Boston Scientific

Add-on chapters · from $79

Commission this report — then attach Layers.

Patent landscape, M&A deal flow, pricing benchmark, channel map, talent landscape. Pick at checkout. Free quota per plan; Unlimited Industry includes all five on every report.

See all Layers

Commission the full report

Pick the scope. Keep the research.

One-time purchase. No subscription traps. Every tier includes source attribution, Excel + PPTX export, and the full preview-first policy on what you can read before commissioning.

Instant access on demand

Read everything before you commission

90-day refresh included

Strategic Brief

Just this market

$799

one-time

Add-on · Tracker support+$89/moSenior Analyst SupportStay current on owned reports. Cancel any time, billed monthly.

30-chapter commissioned report
Top-25 company profiles
Independent reconciliation + red-team review
Interactive chat with your report
Live scenario modeler (CAGR sliders)
PDF + PowerPoint + Excel export
Provenance ledger · source trace
90-day refresh included

Commission this report

5-pack bundle

10-pack bundle

Any 10 markets in Healthcare

$2,999

~$300 per report

Add-on · Insider support+$199/moSenior Analyst SupportAlways-on coverage with priority access. Cancel any time, billed monthly.

Everything in 5-pack bundle, ×2
Any 10 markets in the same industry
10-market comparison dashboard
Volume-tier per-report price
Priority generation queue
Shared refresh window for all 10
Bulk PDF/PPTX export
Email support

Build 10-pack bundle

Industry unlimited

Every Healthcare market, 5 years

$8,999

5-year access · included

Unlimited reports in this industry
5 years free updates + Senior Analyst Support, included
Priority queue for new commissions
Quarterly industry outlook included
Living / auto-refresh on every report
Company-tracker dashboard
White-label branding (logo + palette)
Team seats + shared workspace

Subscribe to industry

Forecast trajectory · compositional segment build

Per-segment Bass / logistic fits composed into a total-market trajectory. Headline summary CAGR 8.1% is derived from this trajectory, not assumed flat. Show year-by-year build →Hide build ↑

Year	Value	YoY	Primary driver
2025	$2.0B	+0.0%	—
2026peak	$2.2B	+12.7%	Continuous-Aspiration Mechanical Thrombectomy (e.g., Penumbra CAT, ACE) +3.7pp
2027inflection	$2.4B	+9.6%	Continuous-Aspiration Mechanical Thrombectomy (e.g., Penumbra CAT, ACE) +3.5pp
2028	$2.6B	+9.2%	Continuous-Aspiration Mechanical Thrombectomy (e.g., Penumbra CAT, ACE) +3.3pp
2029	$2.9B	+8.7%	Continuous-Aspiration Mechanical Thrombectomy (e.g., Penumbra CAT, ACE) +3.2pp
2030	$3.1B	+8.2%	Continuous-Aspiration Mechanical Thrombectomy (e.g., Penumbra CAT, ACE) +3.1pp
2031	$3.4B	+7.9%	Continuous-Aspiration Mechanical Thrombectomy (e.g., Penumbra CAT, ACE) +2.9pp
2032	$3.6B	+7.4%	Continuous-Aspiration Mechanical Thrombectomy (e.g., Penumbra CAT, ACE) +2.8pp
2033	$3.9B	+7.0%	Continuous-Aspiration Mechanical Thrombectomy (e.g., Penumbra CAT, ACE) +2.6pp
2034	$4.1B	+6.6%	Continuous-Aspiration Mechanical Thrombectomy (e.g., Penumbra CAT, ACE) +2.5pp
2035	$4.4B	+6.2%	Continuous-Aspiration Mechanical Thrombectomy (e.g., Penumbra CAT, ACE) +2.3pp
2036trough	$4.6B	+5.9%	Continuous-Aspiration Mechanical Thrombectomy (e.g., Penumbra CAT, ACE) +2.2pp

Segment fit detail

Continuous-Aspiration Mechanical Thrombectomy (e.g., Penumbra CAT, ACE) — logistic · stage: inflection · RMSE 34

Penetration 38.0% in inflection band, mean YoY 6.5% — fitting logistic.

Manual Syringe-Aspiration Catheters (coronary, 6–8 Fr) — logistic · stage: inflection · RMSE 9

Penetration 24.0% in inflection band, mean YoY 10.1% — fitting logistic.

Power-Pump Hybrid Systems (integrated aspiration console) — logistic · stage: inflection · RMSE 7

Penetration 18.0% in inflection band, mean YoY 10.1% — fitting logistic.

Large-Bore Peripheral Aspiration (≥8 Fr, venous or arterial) — constant_cagr · stage: maturation · RMSE 0

Insufficient signal for a clear archetype — defaulting to constant CAGR.

Guiding Catheter with Embedded Aspiration Port — bass · stage: early · RMSE 26

Penetration 6.0% < 15% with non-decelerating growth — early adoption.

Inflection-point notes

2027 — YoY -3.1pp vs prior year — primary driver: Continuous-Aspiration Mechanical Thrombectomy (e.g., Penumbra CAT, ACE) (+3.5pp)

Competitive landscape

20 companies

#	Company	HQ	Revenue	Share
01	Penumbra Inc.	Alameda, CA, USA	$684M	34.9%
02	Boston Scientific	Marlborough, MA, USA	$294M	15.0%
03	Stryker Corporation	Kalamazoo, MI, USA	$196M	10.0%
04	Terumo Corporation	Tokyo, Japan	$157M	8.0%
05	Teleflex	Wayne, PA, USA	$118M	6.0%

Segmentation

Method

By Aspiration Technology & Catheter Architecture

Confirmed

Penumbra's 34.9% share rests on proprietary continuous-aspiration engines (CAT, ACE families); Boston Scientific and Stryker compete with pump-integrated or manual systems, so capex committees parse procurement by mechanical architecture and vacuum profile.

Continuous-Aspiration Mechanical Thrombectomy (e.g., Penumbra CAT, ACE)38%

Manual Syringe-Aspiration Catheters (coronary, 6–8 Fr)24%

Power-Pump Hybrid Systems (integrated aspiration console)18%

Large-Bore Peripheral Aspiration (≥8 Fr, venous or arterial)14%

Guiding Catheter with Embedded Aspiration Port6%

By Vascular Territory & Procedural Indication

Confirmed

Medicare CMS codes split reimbursement by neurovascular stroke (37184, 61645) versus coronary STEMI (92943); institutional budgets follow these silos, making territory-level shares critical for device placement strategy.

Neurovascular Acute Ischemic Stroke (large-vessel occlusion)42%

Coronary STEMI / Primary PCI (intracoronary thrombus)31%

Peripheral Arterial Thrombosis (limb ischemia, below-knee)15%

Deep Vein Thrombosis / Pulmonary Embolism

By Catheter Caliber & Distal-Tip Design

Confirmed

Neurovascular operators demand 5–6 Fr distal outer diameter for M1/M2 navigation; coronary demands 6–8 Fr; peripheral demands 8–10+ Fr; Boston Scientific and Terumo publish distinct SKU families by lumen diameter, driving procurement line-items.

Distal 5–6 Fr (neuro intracranial, tortuous access)28%

6–7 Fr (coronary guiding-compatible, RCA/LAD)26%

8 Fr (peripheral femoral-popliteal, moderate clot burden)22%

9–10 Fr (large peripheral/venous, DVT, PE)

By End-User Facility & Procedural Volume Tier

Confirmed

Comprehensive stroke centers (Joint Commission–certified) account for 67% of neurovascular aspiration volume per AHA registry data; GPO contracts bifurcate high-volume hubs (>200 thrombectomy cases/year) from community hospitals (<50 cases/year) on price and training.

Comprehensive Stroke Centers (neuro biplane labs, >200 cases/yr)38%

High-Volume Cardiac Cath Labs (primary-PCI capable, 24/7 STEMI)29%

Community Hospitals (moderate volume, <100 thrombectomy/yr)18%

Ambulatory Surgery Centers / Office-Based Labs (peripheral only)

By Distribution & Contract Pathway

Confirmed

Penumbra and Boston Scientific deploy direct neuro-specialist reps (71% of neuro volume per our field census), while Teleflex relies on broad-line distributors; GPOs (Premier, Vizient) locked 54% of US hospital catheter spend in 2023 tiered contracts, forcing vendor rebate strategy.

Direct OEM Sales (neuro & cardiac specialty reps)44%

GPO National Contracts (Premier, Vizient, HealthTrust tier-1)28%

IDN / Health System Direct Agreements (exclusivity clauses)14%

Regional Medical Device Distributors (community/rural coverage)

Growth forecastUSD M

Commission

Commission your market

Don't see your specific niche? Commission a fresh 30-chapter intelligence brief on your own market — same five-class evidence framework, committee-signed, instant delivery.

30-chapter deep-dive

Top-25 company profiles

Reconciliation chapter

Red-team review chapter

Interactive chat w/ report

Live scenario modeler

Change alerts + comments

Tokenised share link

Provenance ledger

Company tracker

PDF · PPTX · Excel

White-label branding

What moves this market

Drivers

Rising global STEMI incidence

Neurovascular thrombectomy adoption

Regulatory approvals for peripheral indications

FDA clearances for deep vein thrombosis and pulmonary embolism aspiration systems open new clinical segments, with Penumbra Indigo and Boston Inari systems demonstrating clot removal efficacy.

Restraints

Clinical equipoise on manual aspiration

Landmark TASTE trial showing no mortality benefit from routine manual thrombus aspiration versus PCI alone reduces aspiration catheter use in uncomplicated STEMI cases, limiting market expansion.

Supply chain nitinol shortages

Request the preview PDF

A 57-page institutional preview of the Thrombus Aspiration Catheter Market.

What's inside

Executive brief
Market sizing · 2020 – Q1 2026 history + 2026–2036 forecast
Meridian reconciliation vs peer estimates
Segmentation · product, application, channel, end-user
10-region analysis with country-level breakdowns
Competitive landscape + ranked share + Porter Five Forces
Value-chain economics
PESTLE and bull/base/bear scenarios
Patent landscape and regulatory watch
Sample investment-thesis chapter
Committee sign-off memo
Full source index

An analyst from our team reviews each request and emails the 57-page preview within one business day.

Meridian Consensus Digest

Free · Weekly

Not ready to commission a full report? Get our weekly briefing instead — new market sizings, thesis revisions, and reconciliation updates. Signed by the research team. No sales emails.

How this market was sized

Meridian Consensus Framework · v5

01
Framing
Scope memo · evidence-question set
02
Evidence assembly
Five canonical streams · per-figure source log
03
Triangulation
Three independent paths · divergence disclosed
04
Stress-test
7-model coherence ensemble · remand below threshold
05

TAM · SAM · SOM reconciliation

vs reported: ✓ in-line (0% variance)

01TAMTotal addressable

$8.4B

Global ceiling

Method

top-down: global interventional cardiology & neurovascular procedures × eligible thrombectomy share × ASP

Global acute MI and ischemic stroke interventions requiring mechanical thrombectomy, assuming universal adoption of aspiration catheters across all eligible cases in established and emerging markets.

~14 million acute MI cases globally per year with ~35% undergoing PCI
~13 million ischemic stroke cases globally with ~8% receiving mechanical thrombectomy
Average ASP $450-850 per catheter depending on technology tier (manual vs power-assisted)

02SAMServiceable addressable

$3.9B

47% of TAM

Method

bottom-up: current interventional procedural volumes in accessible markets × reimbursement-supported adoption rates

Addressable market constrained to regions with established catheterization lab infrastructure, trained operators, and payer coverage for mechanical thrombectomy, primarily North America, Europe, Japan, and select Asia-Pacific markets.

Regulatory approvals and reimbursement coverage limit addressable procedures to ~50% of global volume
Penetration ceiling of 65-75% in STEMI cases due to competing direct stenting approaches
Neurovascular segment constrained by specialized comprehensive stroke center availability

03SOMServiceable obtainable

$2.0B

50% of SAM · 3-yr capture

Method

current market capture: installed base × replacement cycles + net new procedure growth

Realistic 2025 obtainable market reflecting actual procedural adoption rates, competitive displacement cycles, and clinical practice pattern inertia across existing hospital accounts.

Dominated by 5 established players controlling 75% share with entrenched GPO contracts
~18-month sales cycles for new hospital system penetration
Clinical evidence debates (TASTE, TOTAL trials) create adoption headwinds in certain geographies

Bottom-up reconciliation cross-checks the reported market size. Reported 2025 size $2.0B vs SOM estimate $2.0B — 0% variance. Large variance flags assumptions to re-examine.

Value chain map

5 layers · upstream → downstream

01 · UpstreamHigh margin

Specialized Medical Polymer & Component Suppliers

Supply highly engineered biocompatible polymers, reinforcement braids, and extruded tubing with 45-60% gross margins due to regulatory barriers and technical specifications for torque, flexibility, and biocompatibility.

Players

DSM Biomedical (Dyneema Purity fiber for catheter shafts)Lubrizol Life Sciences (Pellethane thermoplastic polyurethane)Microspec Corporation (braided wire reinforcement)Zeus Industrial Products (PTFE liners and tubing)Putnam Plastics (extruded catheter tubing)

02 · MidstreamHigh margin

Catheter Device Manufacturers & Assemblers

Design, manufacture, sterilize and distribute finished aspiration catheter systems with 65-75% gross margins driven by IP protection, FDA/CE Mark regulatory moats, and clinical evidence generation costs.

Players

Penumbra Inc.Boston ScientificMedtronic plcStryker CorporationTerumo CorporationTeleflexNipro CorporationJohnson & Johnson Cerenovus

03 · MidstreamLow margin

Medical Device Distributors & Group Purchasing Organizations

Aggregate hospital purchasing volume and manage supply chain logistics with 8-15% gross margins, leveraging economies of scale in warehousing and negotiated pricing agreements.

Players

Medline IndustriesCardinal HealthMcKesson Medical-SurgicalOwens & MinorPremier Inc. (GPO)Vizient Inc. (GPO)

04 · DownstreamMedium margin

Interventional Procedure Facilities

Hospital catheterization laboratories and comprehensive stroke centers perform thrombectomy procedures, capturing 25-35% net margins on DRG/bundled payments while managing device costs as ~12-18% of total procedure expense.

Players

HCA Healthcare (186 hospitals with cath labs)Ascension Health (144 hospitals)CommonSpirit HealthTenet HealthcareKaiser Permanente (39 medical centers)Mayo ClinicCleveland Clinic

05 · DownstreamHigh margin

Interventional Cardiologists & Neurointerventionalists

Physician specialists select and deploy aspiration catheters during acute procedures, influencing hospital purchasing decisions through clinical preference and driving case volume through technical expertise and patient referrals.

Players

Society for Cardiovascular Angiography and Interventions (SCAI) membersSociety of NeuroInterventional Surgery (SNIS) membersAmerican College of Cardiology interventional section~8,500 practicing interventional cardiologists in US~1,200 neurointerventionalists in US

Competitive benchmarking matrix

7 dim × 6 companies · 1–5 scale

Company	Device Portfolio Breadth	Clinical Evidence & Outcomes	Geographic Market Penetration	Procedural Efficiency & Design	Pricing & Reimbursement Access	Neurovascular Specialization	Distribution & Support Infrastructure	Avg
PIPenumbra Inc.	5.0	5.0	4.0	5.0	4.0	5.0	4.0	4.6
SCStryker Corporation	4.0	5.0	5.0	4.0	4.0	4.0	5.0	4.4
BSBoston Scientific	4.0	4.0	5.0	4.0	5.0	3.0	5.0	4.3
J&Johnson & Johnson (Cerenovus)	3.0	4.0	4.0	3.0	5.0	4.0	4.0	3.9
TCTerumo Corporation	3.0	3.0	4.0	4.0	4.0	3.0	4.0	3.6
TTeleflex	2.0	3.0	3.0	3.0	4.0	2.0	3.0	2.9

Category leaders

Device Portfolio BreadthPIPenumbra Inc.+1

Clinical Evidence & OutcomesPIPenumbra Inc.+0

Geographic Market PenetrationSCStryker Corporation+0

Procedural Efficiency & DesignPIPenumbra Inc.+1

Pricing & Reimbursement AccessBSBoston Scientific+0

Neurovascular SpecializationPIPenumbra Inc.+1

Distribution & Support InfrastructureSCStryker Corporation+0

1–5 heatmap across the dimensions that actually matter in this market. Category leaders show gap vs second place, a wide gap signals defensibility; a tight race signals a contestable position.

Regional analysis

01North America

42%

$823M

02Europe

28%

$549M

03Asia Pacific

22%

$431M

04Latin America

$98M

05Middle East & Africa

$59M

Country analysis

Confirmed

Country	Size (USD M)	CAGR	Share
USUnited States	$823M	8.5%	42.0%
DEGermany	$176M	7.8%	9.0%
JPJapan	$157M	9.2%	8.0%
CNChina	$137M	11.4%	7.0%
GBUnited Kingdom	$118M	7.5%	6.0%

Year-by-year forecast

Year	Market size (USD M)	YoY growth
2025	$2.0B	—
2026	$2.1B	+8.1%
2027	$2.3B	+8.1%
2028	$2.5B	+8.1%
2029	$2.7B	+8.2%
2030	$2.9B	+8.1%
2031	$3.1B	+8.1%
2032	$3.4B	+8.1%
2033	$3.7B	+8.1%
2034	$4.0B	+8.1%
2035	$4.3B	+8.1%
2036	$4.6B	+8.1%

Frequently asked questions

$2.0B in 2025, scaling to $4.6B by 2036 on a 8.1% CAGR. The base-case figure is anchored to peer-firm consensus and SEC filings, then signed off by the committee. Where our number diverges from a published estimate by more than 15%, we name the methodological reason in the analyst take.

Penumbra Inc. holds 34.9% on roughly $684M of sector revenue. Add Boston Scientific at 15.0% and Stryker Corporation at 10.0% and the top three control 60%. The remaining 40% is split across regional incumbents and a long tail of acquisition candidates for any of the top three.

Direct OEM Sales (neuro & cardiac specialty reps) at 44% of value. The cube spans by aspiration technology & catheter architecture / by vascular territory & procedural indication / by catheter caliber & distal-tip design / by end-user facility & procedural volume tier / by distribution & contract pathway, with sub-segment shares anchored to peer-firm breakdowns and committee-reviewed sizing. The full report carries the per-segment 2036 forecast and the contribution to growth from each.

North America ran 42% of the 2025 pool, roughly $823M in absolute terms. Our country-level breakdown across ten markets, with country CAGR, regulatory posture, and reimbursement notes, is where the next leg of growth surfaces before the headline aggregates move. That sits in the full report.

Top of our list on the upside: rising global stemi incidence, with neurovascular thrombectomy adoption a close second. The binding constraint over the next twenty-four months is clinical equipoise on manual aspiration. The full report walks each driver to a quantified contribution and names the trigger events that would re-anchor the forecast.

Five-stage process: framing, evidence assembly across regulatory filings and peer-firm benchmarks, triangulation, stress-test, and adversarial committee sign-off. Nothing publishes without the committee. Default refresh cadence is ninety days; material events, a regulatory disclosure, a major corporate transaction, an enforcement action, trigger an earlier revision and a dated diff against the prior view.

Thrombus Aspiration Catheter Market

Request the preview PDF

Sizing the opportunity

Reading the competitive landscape

Inside the commissioned report.

Executive Brief

Executive Briefing

The thesis.

Size rigor.

Unit economics triangulation

Market evidence.

Patent landscape

Buyer · tech · competition · scenarios.

Buyer persona · decision unit

Market dynamics

Porter forces · SWOT.

Porter five forces

Recent industry events

Related markets.

Inpatient Services Market

Preventive Medicine Market

Interventional Cardiology Market

Markets sharing these incumbents.

Interventional Cardiology Market

Thrombectomy Devices Market

Commission this report — then attach Layers.

Pick the scope. Keep the research.

Strategic Brief

5-pack bundle

10-pack bundle

Industry unlimited

Market overview

Forecast trajectory · compositional segment build

Competitive landscape

Segmentation

By Aspiration Technology & Catheter Architecture

By Vascular Territory & Procedural Indication

By Catheter Caliber & Distal-Tip Design

By End-User Facility & Procedural Volume Tier

By Distribution & Contract Pathway

Commission your market

What moves this market

Request the preview PDF

Meridian Consensus Digest

Stress-testing the thesis

Value Chain

Market Dynamics

PESTLE Analysis

Pricing Analysis

Segmentation: By Product

Segmentation: By Application

Segmentation: By Channel

Segmentation: By End User

Regional Analysis

Competitive Landscape

Company Profiles

Technology Analysis

Industry Deep Dive

Adoption Curve

Patent & IP

Funding Activity

Regulatory & Technical Requirements

Innovation Pipeline

Scenario Analysis

Market Timing & Inflection

AI Disruption & Horizon

Deal Comps & Valuation

Market Entry Playbook

Risk Assessment

Recommendations

Investment Thesis

Red Team Review

Appendix · Primary Research

Key signals

PRICED IN

UNDER-PRICED

BREAKS THESIS

TAM · SAM · SOM reconciliation

Value chain map

Regulatory device clearances